New test helps doctors ID kidney disease cause

(HealthDay)—A new test that helps doctors identify the cause of a specific type of kidney disease has been approved by the U.S. Food and Drug Administration.

Membranous glomerulonephritis (MGN) damages blood vessels in the kidneys that help filter the blood. Some cases are caused by the body's rejection of its own (autoimmune), while the rest are triggered by other causes such as infection, the FDA said in a news release.

The Euroimmun Anti- Pla2r IFA test detects an antibody that is present if the cause of MGN is autoimmune, the FDA said.

In a clinical study of 560 blood samples, the test detected autoimmune cases of MGN in 77 percent of samples donated by people presumed to have this form, the agency said.

The test should not be the sole determinant of MGN's cause, nor should a negative test rule out a specific cause, the FDA said.

The test is manufactured by Euroimmun US, based in Morris Plains, N.J.

More information: Visit the FDA to learn more.

add to favorites email to friend print save as pdf

Related Stories

New test IDs genotype of hepatitis C

Jun 20, 2013

(HealthDay)—A new test to help doctors identify the genotype of a person's hepatitis C infection has been approved by the U.S. Food and Drug Administration.

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments